Sofinnova Partners SAS 3
3 · CinCor Pharma, Inc. · Filed Jan 6, 2022
Insider Transaction Report
Form 3
Sofinnova Partners SAS
10% Owner
Holdings
- (indirect: By Sofinnova Capital IX)
Series A Preferred Stock
→ Common Stock (2,941,176 underlying) - (indirect: By Sofinnova Capital IX)
Series B Preferred Stock
→ Common Stock (926,470 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- [F2]The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.